Julius Clinical
Julius Clinical is a science-led, therapeutically specialized CRO providing Phase I-IV clinical trials, real-world evidence, and epidemiology services to pharmaceutical, biotech, and public health clients, with core focus on neurological, cardio-metabolic, and infectious disease programs across 25+ countries.
- Company typePrivate
- Founded2008
- HeadquartersZeist, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Julius Clinical does
Julius Clinical is a Netherlands-headquartered, science-led Contract Research Organization (CRO) founded in 2008 as a spin-off from the University Medical Center Utrecht. The company provides Phase I-IV clinical trial services, real-world evidence (RWE) and epidemiology studies, and electronic medical record (EMR) data integration for pharmaceutical, biotechnology, and public health clients. It is therapeutically specialized in three core areas: neurological diseases (Alzheimer's, ALS, dementia, hearing loss, pain, seizures), cardio-metabolic and renal diseases (chronic kidney disease, dyslipidemia, MASH/NASH, type 2 diabetes, cardiovascular outcomes trials), and infectious diseases and vaccines (RSV, vaccine development, post-licensure safety studies). The company is majority-owned by Ampersand Capital Partners following a November 2023 investment and operates a "triangle" model combining scientific leadership, global site networks spanning 25+ countries, and operational delivery.
The business operates on a professional services revenue model with quote-based, project-negotiated pricing across three engagement tiers: full-service, functional-service (FSP), and single-service. The go-to-market is enterprise field sales targeting large pharmaceutical companies, mid-sized biotech innovators, and public health institutions, supported by scientific thought leadership including peer-reviewed publications, webinars, industry conferences, and case studies. Following the May 2025 merger with Peachtree BioResearch Solutions (CNS-focused US CRO) and the November 2025 merger with P95 (epidemiology and vaccine specialist), the combined organization comprises over 500 professionals operating across five continents, having executed 400+ clinical trials enrolling 300,000+ subjects. The platform incorporates AI and natural language processing (NLP) for EMR/EHR-based patient eligibility screening, external control arm construction, and feasibility analysis, though AI is a workflow enabler rather than a standalone product offering.
Julius Clinical firmographics
Firmographics- Name
- Julius Clinical
- Legal name
- Julius Clinical Research B.V.
- Website
- https://juliusclinical.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Julius Clinical is a science-led, therapeutically specialized CRO providing Phase I-IV clinical trials, real-world evidence, and epidemiology services to pharmaceutical, biotech, and public health clients, with core focus on neurological, cardio-metabolic, and infectious disease programs across 25+ countries.
- Ownership category
- akta.pro rank
Julius Clinical industry classification
Industry- Product category
- Clinical Research Services (CRO)
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)
Keywords
Where Julius Clinical is headquartered
LocationHeadquarters
- HQ city
- Zeist
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Julius Clinical business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Services: Full-service, functional-service, and single-service clinical research organization (CRO) services for pharmaceutical, biotech, and medical device companies. Services span Phase I-IV clinical trials, epidemiology studies, and real-world evidence projects.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Julius Clinical product offering
Product offeringCore offering
Julius Clinical is a science-led Contract Research Organization (CRO) that delivers Phase I-III clinical trials, epidemiology studies, and real-world evidence programs for pharmaceutical, biotech, and public health clients across three core therapeutic areas: neurological diseases, cardio-metabolic and renal diseases, and infectious diseases and vaccines. The company combines scientific leadership, global site networks, and operational delivery through full-service, functional-service, and single-service engagement models, supported by AI/NLP-enabled EMR data integration. Post-merger with P95 in November 2025, the combined organization operates across more than 25 countries with over 500 professionals.
Product overview
Julius Clinical is a science-led Contract Research Organization (CRO) offering integrated clinical development and real-world evidence solutions through a unique triangle model combining scientific leadership, site networks, and delivery excellence. The portfolio spans three core therapeutic areas: Neurological diseases (including Alzheimer's, ALS, dementia), Cardio-Metabolic and Renal diseases (including MASH, diabetes, CKD), and Infectious Diseases & Vaccines. Following the 2025 merger with P95 and Peachtree BioResearch Solutions, the company now operates as a global full-service CRO with flexible engagement models (full-service, functional-service, and single-service) across 25+ countries. Key service offerings include Phase I-III clinical trials, epidemiology and RWE studies, and EMR/EHR data integration using AI/NLP capabilities for patient eligibility and external control arms.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Development Services
Quantifiable outcome
- 23% lower risk of death from any cause with high-dose hemodiafiltration vs hemodialysis (CONVINCE trial published in NEJM)
- +2 more outcomes
Companies that use Julius Clinical
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles3 records
Julius Clinical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
Julius Clinical partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- P95coreP95 merged with Julius Clinical to form a global, science-led CRO with integrated expertise in neuroscience, cardio-renal-metabolic, and infectious diseases/vaccines. P95 brings leadership in epidemiology, RWE, and vaccine development, with 300 staff across 30 countries.
- Peachtree BioResearch SolutionscorePeachtree BioResearch Solutions, a specialized CNS CRO based in Georgia, USA, merged with Julius Clinical to create a fully integrated global CRO with increased CNS capabilities. The merger combines extensive expertise in managing Phase I-III clinical studies with particular depth in CNS, cardio-metabolic, renal, and rare diseases.
- GRIPonMASH ConsortiumcoreEuropean research consortium of 27 institutions focused on early detection and understanding of MASLD/MASH. Julius Clinical co-founded the consortium and leads Work Package 2 for screening studies. The 26-million-euro project is funded by IHI JU and includes academic institutions and industry partners.
- Leiden University Medical CenterminorCollaborated on the AwareNASH survey project to explore healthcare workers' knowledge, practices, and attitudes toward NAFLD/NASH diagnosis and management across 88 countries.
- ReSViNETminorPartner organization for RSV-related webinars including 'RSV and Asthma' and 'Progress in RSV Vaccines and Monoclonal Antibodies'.
- EsperionminorCollaboration on analysis of CLEAR trial outcomes investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular complications.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
Julius Clinical competitors and assessment
Company assessmentDirect peers
- Medpace Holdings: Mid-sized specialty CRO with a similar full-service, therapeutically focused operating model serving small-to-mid biotech and large pharma; highly relevant comparable given overlapping therapeutic depth and similar enterprise positioning.
- Worldwide Clinical Trials: Specialty CRO with deep CNS and cardiometabolic expertise offering full-service and functional-service models; directly comparable therapeutic focus and mid-sized private-company profile.
- TFS HealthScience: Specialty CRO focused on CNS, dermatology, ophthalmology and oncology with flexible engagement models; the new CEO Bassem Saleh was formerly CEO here, making it a closely comparable operating model.
- Premier Research: Specialty CRO with therapeutic depth in CNS, oncology and rare disease serving small-to-mid biotech; comparable mid-sized private CRO profile and therapeutic overlap.
Broad incumbents
- ICON plc: One of the largest global CROs offering full-service clinical development across all therapeutic areas; competes head-to-head with Julius Clinical for large pharma CNS and cardio-metabolic trials but with materially greater scale.
- IQVIA: Largest global CRO with integrated R&D services, real-world evidence, and technology platforms; competes across all of Julius Clinical's therapeutic areas with substantially broader operational footprint.
- Parexel International: Large full-service CRO with deep CNS, oncology, and rare disease capabilities; comparable therapeutic focus but materially larger scale and broader geographic coverage.
- Syneos Health: Full-service biopharmaceutical solutions provider offering clinical development and commercialization services; broader scope than Julius Clinical but overlaps in CNS and cardio-metabolic trial execution.
- Charles River Laboratories: Broad life sciences services organization with CRO capabilities in early-stage and clinical research; competes in CNS and rare disease trials with a wider services portfolio spanning discovery through clinical.
Emerging players
- Ergomed: Specialty CRO with focus on oncology and rare disease that was acquired by IQVIA in 2024; historically comparable mid-sized specialty CRO model now operating within the IQVIA platform.
Market position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Julius Clinical social profiles
Digital presenceJulius Clinical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Julius Clinical leadership team
Management profileNumber of profiles
Profiles11 records
Julius Clinical subsidiaries and ownership
Company hierarchySubsidiaries1 record
Julius Clinical funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Julius Clinical M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Julius Clinical
What does Julius Clinical do?
Julius Clinical is a science-led Contract Research Organization (CRO) that delivers Phase I-III clinical trials, epidemiology studies, and real-world evidence programs for pharmaceutical, biotech, and public health clients across three core therapeutic areas: neurological diseases, cardio-metabolic and renal diseases, and infectious diseases and vaccines. The company combines scientific leadership, global site networks, and operational delivery through full-service, functional-service, and single-service engagement models, supported by AI/NLP-enabled EMR data integration. Post-merger with P95 in November 2025, the combined organization operates across more than 25 countries with over 500 professionals.
Is Julius Clinical a public or private company?
Julius Clinical is a private company. It is classified as private equity controlled and is currently operating.
When was Julius Clinical founded?
Julius Clinical was founded in 2008. It employs 101 to 250 people.
Where is Julius Clinical based?
Julius Clinical is headquartered in Zeist, Netherlands, in the Europe region.
How does Julius Clinical make money?
One revenue line is on record: clinical Trial Services.
Who are Julius Clinical's main competitors?
Direct peers on record are Medpace Holdings, Worldwide Clinical Trials, TFS HealthScience and Premier Research. Broad incumbents are ICON plc, IQVIA, Parexel International, Syneos Health and Charles River Laboratories. Ergomed is listed as an emerging player.
Does Julius Clinical have an API?
No public API is recorded for Julius Clinical.
What industry is Julius Clinical in?
Julius Clinical's product category is Clinical Research Services (CRO). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54171 and its SIC code is 8731.